Lee-Shing Chang

Lee-Shing Chang

Auto-generated profile, based on publicly available information

Lee-Shing Chang

Endocrinology Division, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2018 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
LCLee-Shing Chang
Lee-Shing Chang
RBRomualdo Barroso-Sousa
Romualdo Barroso-Sousa
STSara M Tolaney
Sara M Tolaney
FHF Stephen Hodi
F Stephen Hodi
UKUrsula B Kaiser
Ursula B Kaiser
LMLe Min
Le Min
Immune checkpoints are small molecules expressed by immune cells that play critical roles in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) with inhibitory antibodies has demonstrated effective and durable antitumor activity in subgroups of patients with cancer. The US Food and Drug Administration has approved several immune checkpoint inhibitors (ICPis) for the treatment of a broad spectrum of malignancies. Endocrinopathies have emerged as one of the most common immune-related adverse events (irAEs) of ICPi therapy. Hypophysitis, thyroid dysfunction, insulin-deficient diabetes mellitus, and primary adrenal insufficiency have been reported as irAEs due to ICPi therapy. Hypophysitis is particularly associated with anti-CTLA-4 therapy, whereas thyroid dysfunction is particularly associated with anti-PD-1 therapy. Diabetes mellitus and primary adrenal insufficiency are rare endocrine toxicities associated with ICPi therapy but can be life-threatening if not promptly recognized and treated. Notably, combination anti-CTLA-4 and anti-PD-1 therapy is associated with the highest incidence of ICPi-related endocrinopathies. The precise mechanisms underlying these endocrine irAEs remain to be elucidated. Most ICPi-related endocrinopathies occur within 12 weeks after the initiation of ICPi therapy, but several have been reported to develop several months to years after ICPi initiation. Some ICPi-related endocrinopathies may resolve spontaneously, but others, such as central adrenal insufficiency and primary hypothyroidism, appear to be persistent in most cases. The mainstay of management of ICPi-related endocrinopathies is hormone replacement and symptom control. Further studies are needed to determine (i) whether high-dose corticosteroids in the treatment of ICPi-related endocrinopathies preserves endocrine function (especially in hypophysitis), and (ii) whether the development of ICPi-related endocrinopathies correlates with tumor response to ICPi therapy.

27 September 2021 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
ASAna Maria Stanton
Ana Maria Stanton
MVMuthiah Vaduganathan
Muthiah Vaduganathan
LCLee-Shing Chang
Lee-Shing Chang
ATAlexander Turchin
Alexander Turchin
JJJames Januzzi
James Januzzi
VAVanita R. Aroda
Vanita R. Aroda

13 April 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
AZAmy L. Zhang
Amy L. Zhang
Fang WangFang Wang
Fang Wang
LCLee-Shing Chang
Lee-Shing Chang
MMMarie E. McDonnell
Marie E. McDonnell
LMLe Min
Le Min
Autoimmune diabetes is a rare but severe endocrine toxicity induced by immune checkpoint inhibitor (ICI) treatment. It is unclear if ICI causes selective islet toxicity or non-selective pancreas toxicity. We analyzed 11 patients treated with ICI who developed ICI-related autoimmune diabetes. Eight patients had lipase and/or amylase tested on the same day of diagnosis of autoimmune diabetes. Among them, 75% (6/8) had normal lipase and 100% (6/6) had normal amylase. There was no correlation between glucose level at onset and biochemical pancreatitis. We characterized the clinical features of ICI-induced autoimmune diabetes. Fifty-five percent (6/11) of patients tested positive for GAD65 autoantibodies, and 55% (6/11) developed diabetic ketoacidosis at manifestation of hyperglycemia. In all 11 patients, C-peptide levels were low in the presence of hyperglycemia. ICI-induced thyroiditis was found in 64% (7/11), of which 36% (4/11) were newly diagnosed with thyroiditis while the remaining 27% (3/11) had pre-existing hypothyroidism followed by ICI-induced thyroiditis. Additionally, 27% (3/11), developed ICI-induced hypophysitis. Thyroiditis and autoimmune diabetes coexisted in all patients with ICI-induced hypophysitis. The median time from ICI treatment to the onset of autoimmune diabetes was 11 weeks. Our data suggest that few patients had coexistent ICI-induced autoimmune diabetes and pancreatitis, suggesting ICI mainly caused selective islet toxicity.

4 December 2019 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
LCLee-Shing Chang
Lee-Shing Chang
MVMuthiah Vaduganathan
Muthiah Vaduganathan
JPJorge Plutzky
Jorge Plutzky
VAVanita R. Aroda
Vanita R. Aroda

2 August 2017 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
LCLee-Shing Chang
Lee-Shing Chang
MYMaria A. Yialamas
Maria A. Yialamas

1 February 2024 in Primary Care Diabetes
Verified
Journal Article
Open access
ABAlexander J. Blood
Alexander J. Blood
LCLee-Shing Chang
Lee-Shing Chang
CCCaitlin Colling
Caitlin Colling
GSGretchen Stern
Gretchen Stern
DGDaniel Gabovitch
Daniel Gabovitch
BSBenjamin M. Scirica
Benjamin M. Scirica
Describe the rationale for and design of Diabetes Remote Intervention to improVe use of Evidence-based medications (DRIVE), a remote medication management program designed to initiate and titrate guideline-directed medical therapy (GDMT) in patients with type 2 diabetes (T2D) at elevated cardiovascular (CV) and/or kidney risk by leveraging non-physician providers. An electronic health record based algorithm is used to identify patients with T2D and either established atherosclerotic CV disease (ASCVD), high risk for ASCVD, chronic kidney disease, and/or heart failure within our health system. Patients are invited to participate and randomly assigned to either simultaneous education and medication management, or a period of education prior to medication management. Patient navigators (trained, non-licensed staff) are the primary points of contact while a pharmacist or nurse practitioner reviews and authorizes each medication initiation and titration under an institution-approved collaborative drug therapy management protocol with supervision from a cardiologist and/or endocrinologist. Patient engagement is managed through software to support communication, automation, workflow, and standardization. We are testing a remote, navigator-driven, pharmacist-led, and physician-overseen management strategy to optimize GDMT for T2D as a population-level strategy to close the gap between guidelines and clinical practice for patients with T2D at elevated CV and/or kidney risk.